| AAVs | Adeno-Associated Viruses |
| ACC | American College of Cardiology |
| ACE | Angiotensin-Converting Enzyme |
| ACEis | Angiotensin-Converting Enzyme inhibitors |
| AF | Atrial Fibrillation |
| ARBs | Angiotensin Receptor Blockers |
| ARNI | Angiotensin Receptor Blocker/Neprilysin Inhibitors |
| BNP | B-type Natriuretic Peptide |
| BP | Blood Pressure |
| CAD | Coronary Artery Disease |
| CHF | Congestive Heart Failure |
| CRP | C-Reactive Protein |
| CRT | Cardiac Resynchronization Therapy |
| GDMT | Guideline-Directed Medical Therapy |
| HF | Heart Failure |
| HfrEF | Heart Failure with reduced Ejection Fraction |
| HR | Heart Rate |
| ICDs | Implantable Cardioverter-Defibrillators |
| LV | Left Ventricular |
| LVEF | Left Ventricular Ejection Fraction |
| MI | Myocardial Infarction |
| MPCs | Mesenchymal Precursor Cells |
| MRAs | Mineralocorticoid Receptor Antagonists |
| NNT | Number Needed to Treat |
| NT-proBNP | N-Terminal pro-B-type Natriuretic Peptide |
| NYHA | New York Heart Association |
| RAAS | Renin/Angiotensin/Aldosterone System |
| SCD | Sudden Cardiac Death |
| SGLT2i | The use of sodium glucose cotransporter 2 inhibitors |